RenovoRx Q2 revenue $909k, up 115% YoY; raises FY26 guidance to $3.75-4.25M

RenovoRx, Inc.

Q2 2026 revenue $909k, up 61% QoQ and 115% YoY; gross margin 84.3%.
FY2026 revenue guidance raised to $3.75M-$4.25M from prior $3.0M-$4.0M.
Phase III TIGeR-PaC fully enrolled; completion expected H1 2027, topline H2 2027.
First commercial RenovoCath use in sarcoma; active cancer centers up to 21 from 16.
Net loss $2.9M ($0.06/share); cash $9.5M, sufficient into H2 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.